Best Oncology Companies in Pennsylvania, United States

Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.​

Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.

Biotech developing small molecule therapies for cancer, guided by clinical experience. The company identifies and develops innovative treatments for various cancers by listening to and learning from clinical experiences. This approach leads to the identification of new therapeutic targets. They focus on translating clinical insights into effective therapies, with a commitment to advancing drug candidates into human trials safely and quickly. Their team possesses diverse skills and expertise to drive the development of transformative cancer treatments. They are dedicated to improving patient outcomes through innovative science and a deep understanding of the clinical landscape. The company is focused on small molecule agents, clinical experience, therapeutic targets, and cancer treatment.

Funding rounds

• Feb 2026Series B$5M
• Aug 2025Series B$1.3M
• Jan 2025Grant (prize money)$1000K
• Aug 2024Series B$5.8M

Founders & team

Christopher NataleCo-FounderTodd RidkyCo-FounderPatrick MooneyCEO

Investors

Kairos Ventures, University of Pennsylvania, HHS, Springboard Enterprises

Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity. This biopharmaceutical company is dedicated to turning the complexity of solid tumors against themselves through personalized, whole tumor-derived immunotherapies. Their unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells. They are developing a diverse pipeline of personalized treatments with promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors. The company focuses on research & development strategy and activities, clinical development, and potential product development to deliver therapies targeting solid tumors. They are committed to innovation in the field of personalized immunotherapy.

Funding rounds

• Jan 2025Series C$29M
• Sep 2023Series C$23M
• Jul 2020Series C$112.4M
• May 2019Series B$24.8M

Founders & team

David AndrewsCo-Founder & Chief Medical Officer

Investors

Magnetar, Invus, TLP Invest, Hp Wild Holding, Ziff Capital Partners, Reimagined Ventures

Developing small molecule therapeutics for cancer and inflammatory diseases. The company focuses on orally available treatments, particularly sphingosine kinase inhibitors, targeting solid tumors and chronic inflammatory conditions. Their research and development efforts are centered around a clinical lead compound with potential efficacy in viral infections and inflammatory damage reduction. The company's technology offers promise as an add-on therapy to existing standard of care drugs, demonstrating additive or synergistic effects in preclinical models. The company is dedicated to advancing innovative therapies for significant unmet medical needs, with a focus on improving patient outcomes in oncology and inflammatory disease management.

Funding rounds

• Nov 2025Grant (prize money)$1.7M
• Aug 2023Grant (prize money)$1.7M
• Aug 2019Grant (prize money)$225K
• Sep 2014Grant (prize money)$1.1M

Founders & team

Charles SmithFounder

Investors

HHS

Developer of therapies for cancer treatment. The company's lead candidate FORE8394 is a small-molecule, next-generation, orally available selective inhibitor of mutated BRA for the treatment of tumors.

Developer of diagnostic tool predicting genomic biomarkers from digital histological tissue slides. The tool uncovers morphological patterns to accelerate biomarker screening. It provides genomic test results, potentially unlocking precision therapies. The technology aims to empower oncologists to make precision therapy a reality for more patients.

Funding rounds

• Mar 2026Seed$4.3M

Founders & team

Catherine ECo-Founder & CTOMagda MCo Founder and Board MemberRick SVice President

Investors

TK & Partners, Mesa Verde Venture Partners, Nfcr, Afcr, Bootstrap Venture Partners

Developer of a novel therapeutic focused on cancer cell metabolism. The therapeutic selectively disrupts the energy metabolism of cancer cells, leading to cell death. It impacts nuclear factor-κB, which affects cancer cells’ ability for protein synthesis and DNA transcription, restricting cell growth. The therapeutic has shown pro-inflammatory cytokine suppression in preclinical studies. It is focused on the treatment of ovarian and pancreatic cancers.

Funding rounds

• Feb 2026Seed$1.6M

Founders & team

Greg BoschFounder & CEO

Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions. The company provides a diagnostic technology platform designed to empower healthcare professionals with the capability to perform various tests directly at their clinics. This innovative system utilizes a portable, multi-modality reader and application-specific cartridges to deliver timely, accurate, and comprehensive healthcare within a single visit. The platform supports immunoassay, chemistry, and molecular assays, as well as complete blood cell counts. The fully automated system minimizes user errors and provides rapid results, enhancing efficiency and improving patient outcomes. This technology offers a single device solution, reducing the need for multiple systems and extensive training. The platform features wireless connectivity and electronic medical record compatibility, facilitating seamless integration into existing healthcare workflows. This is a B2B tech company in the healthcare industry.

Funding rounds

• May 2025Grant (prize money)$4.1M
• Sep 2021Grant (prize money)$1M
• Jul 2020Grant (prize money)$4.1M
• Feb 2020Grant (prize money)$225K

Founders & team

Johann deSaFounder

Investors

National Science Foundation, Ben Franklin Technology Partners, HHS, Military Health

Tech stack

WordpressMysqlPhpAnimate.CssWpbakeryJetpack

Provider of circulating cell-free DNA (cfDNA) for cancer screening. The company has developed qPCR assays for tumor DNA markers using cfDNA in urine and blood, and robust methods for cfDNA isolation. The first application is the non-invasive screening and monitoring of hepatocellular carcinoma. Additional diagnostic tests for colon, pancreatic, and lung cancer are also under development.

Funding rounds

• Apr 2025Grant (prize money)$604.2K
• Aug 2023Grant (prize money)$406.5K
• Mar 2023Grant (prize money)$595.8K
• Dec 2021Grant (prize money)$604.2K

Founders & team

Frank SongFounder

Investors

HHS

Developer of small-molecule innate immune modulators for cancer therapy. It discovers and develops orally available drug candidates that target enzymes and pathways in the innate immune system to treat solid tumors and autoimmune diseases. Its pipeline includes AVA-NP-695 which is ENPP inhibitors and AVA-ADR-001 ADAR inhibitors designed to provide antitumor activity and synergy with checkpoint inhibitors and radiation.

Funding rounds

• May 2025Series A$12M
• Jul 2022Series A—
• Mar 2022Series A—
• Jul 2019Series A—

Founders & team

Aditya KulkarniCo-Founder & CSOArun PapaiahCo-Founder & CEONamala SrinivasanCo-Founder & Director

Investors

JITO Incubation & Innovation Foundation, TCA, Capital 2B, Shastra, IvyCap Ventures, 1Crowd

Tech stack

Apache Http ServerBootstrapCloudflareFont AwesomeGoogle AnalyticsHsts

Developer of lipid-based therapies for common bladder syndromes. It offers products that target intravesical therapy for the urinary bladder lumen via urethral catheterization. Indications targeted include interstitial cystitis, overactive bladder and superficial bladder cancer. The products consist of liposome formulations of large multilamellar liposomes made from sphingomyelin lipids which bind to sphingomyelin in the bladder wall, forming a lipid barrier. This protective coating promotes healing and prevents further damage to the bladder wall from urinary toxins.